Welichem Biotech Inc.

Glaxo Group Limited

Therexcell Pharma Inc.

Wei Liu

Genhui Chen

Jianxiong Li

John M Webster

Jiang Zhu

Kaji Hu

Bernard A MacLeod

Ernest Puil

Thomas Michael Stokes

Malcolm John Webster

The invention provides novel 1,2-diphenylethene derivatives and pharmaceutically acceptable salts thereof, the process for production of these compounds and their pharmaceutical composition and the use of these compounds as modulators of T-cells, neutrophils, macrophages and their associated cytokines as agents for treating immune, inflammatory and auto-immune diseases.

1,2-diphenylethene derivatives for treatment of immune diseases

The invention provides for the use of isovaline or a pharmaceutically acceptable salt thereof for the treatment of Pain in a mammalian subject in some preferred embodiments, the invention provides for the treatment of acute and chronic Pain syndromes where other drug therapies have limited efficacy or unacceptable toxicity in said subject.

Isovaline for treatment of pain

The present invention provides novel methods of treating psoriasis, protein tyrosine kinase-associated disorders, inflammation, epidermal hyperproliferation, diabetes, immune and autoimmune diseases, eczema, and inflammatory bowel disease, inhibiting protein kinase, neutrophil activation, cell proliferation, tumour growth, metastasis, and the development of atheromatous plaque and restonosis, controlling angiogenesis, and preventing inflammatory bowel disease, using hydroxystilbenes and novel stilbene derivatives.

Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues

The present invention provides novel diphenyl ethene compounds and pharmaceutically-acceptable salts thereof. Also provided are methods for making the compounds of the invention as well as methods for the use thereof in the treatment of immune, inflammatory, and auto-immune diseases.

Growing community of inventors

Coquitlam, Canada

Wei Liu